--- title: "Nanobiotix, whose stock price has surged over 700% in a year, welcomes acquisition catalysts as Johnson & Johnson shows interest" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280469800.md" description: "Nanobiotix's stock price rose due to Johnson & Johnson's consideration of an acquisition, climbing about 7% at one point on the Paris stock market on Wednesday, and increasing over 15% in pre-market trading in the U.S. Nanobiotix has a long-term partnership with Johnson & Johnson to develop the next-generation core asset JNJ-1900 (NBTXR3). Over the past year, Nanobiotix's stock price has surged over 700%, with a market capitalization of approximately $1.5 billion, focusing on physics-driven nano tumor treatments" datetime: "2026-03-25T12:11:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280469800.md) - [en](https://longbridge.com/en/news/280469800.md) - [zh-HK](https://longbridge.com/zh-HK/news/280469800.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280469800.md) | [English](https://longbridge.com/en/news/280469800.md) # Nanobiotix, whose stock price has surged over 700% in a year, welcomes acquisition catalysts as Johnson & Johnson shows interest According to the well-known French publication "La Lettre," American pharmaceutical giant Johnson & Johnson (JNJ.US) is considering making an acquisition offer for a French cancer drug developer, leading to a nearly 7% increase in the stock price of Nanobiotix (NBTX.US) on the Paris stock market on Wednesday, and a rise of over 15% in pre-market trading in the U.S. Based in Paris, Nanobiotix currently has a partnership with global healthcare leader Johnson & Johnson, under which they are jointly developing and commercializing its next-generation core asset JNJ-1900 (NBTXR3) based on a long-term licensing agreement signed in 2023 with the New Jersey-based pharmaceutical company. Last October, the company's stock price surged significantly due to preliminary results from a Phase 1 clinical trial aimed at evaluating this intratumoral injection therapy as a key component of a combination treatment for a type of esophageal cancer known as locally advanced esophageal adenocarcinoma. In the recently concluded year of 2025, Nanobiotix's stock price and market capitalization have increased by over 700%, bringing its latest market capitalization to approximately $1.5 billion. Nanobiotix is essentially a French late-stage clinical oncology biotech company that does not focus on traditional small molecules or antibody drugs but rather on a "physically driven nanotherapy platform." Its most important core asset is NBTXR3/JNJ-1900: a candidate product composed of functionalized hafnium oxide nanoparticles that, after a single intratumoral injection into the tumor, enhances energy deposition within the tumor under radiation therapy, thereby improving the efficiency of radiation in killing tumor cells while minimizing radiation damage to surrounding normal tissues. The company's current main business revolves around this large platform of "radiation sensitization/radiation enhancement," advancing clinical development across multiple solid tumors such as head and neck cancer, lung cancer, esophageal cancer, and pancreatic cancer, and attempting to establish it as a foundational technology for tumor treatment that can be expanded across cancer types. In 2025, the company continuously released positive clinical signals, which is the core logic behind its stock price surge of 700% over the past year; for example, preliminary Phase 1 data for esophageal cancer showed good treatment tolerance, with an 85% disease control rate and a 69% objective response rate among 13 patients; the company also continued to advance in indications such as pancreatic cancer and lung cancer during the same period. In 2023, Johnson & Johnson's Janssen signed a global co-development and commercialization licensing agreement with Nanobiotix, and in March 2025, the agreement was revised, relieving Nanobiotix of the funding obligations for the key Phase III head and neck cancer study NANORAY-312, extending the cash visibility period to mid-2026, significantly alleviating the most lethal financing pressure faced by clinical biotech companies. If the JNJ-1900 asset or Phase III head and neck cancer or subsequent multi-cancer data continues to be positive, a direct acquisition by Johnson & Johnson would be more advantageous for controlling global rights, pricing power, and subsequent indication expansion than a long-term revenue-sharing arrangement. In other words, what attracts Johnson & Johnson to Nanobiotix is not just a single product, but the potential behind it to be amplified into a new paradigm of tumor radiation enhancement through its physical nanotherapy platform ### 相關股票 - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [Nanobiotix SA (NBTX.US)](https://longbridge.com/zh-HK/quote/NBTX.US.md) - [Johnson & Johnson (JNJ.US)](https://longbridge.com/zh-HK/quote/JNJ.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) ## 相關資訊與研究 - [Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process](https://longbridge.com/zh-HK/news/280509196.md) - [BUZZ-Nanobiotix jumps after media report says J&J mulls potential takeover](https://longbridge.com/zh-HK/news/280444847.md) - [BUZZ-Sarepta rises after muscle disease drugs show promise in early-to-mid stage trials](https://longbridge.com/zh-HK/news/280470791.md) - [J&J wins FDA approval for Icotyde to enter psoriasis pill market](https://longbridge.com/zh-HK/news/279918577.md) - [BUZZ-Hoth Therapeutics rises as skin treatment shows promise in cancer patients](https://longbridge.com/zh-HK/news/280315364.md)